Semglee vs. Basaglar

Semglee (insulin glargine injection) and Basaglar (insulin glargine injection) are long-acting human insulin analogs indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Side effects of Semglee and Basaglar that are similar include low blood sugar (hypoglycemia), allergic reactions, injection site reactions, changes in body fat distribution (lipodystrophy), itching, rash, fluid retention (edema), and weight gain.

Side effects of Basaglar that are different from Semglee include upper respiratory tract infection, runny or stuffy nose, back pain, cough, urinary tract infection (UTI), diarrhea, depression, and headache.

Both Semglee and Basaglar may interact with antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors (MAOIs), pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, alcohol, beta-blockers, clonidine, lithium salts, guanethidine, and reserpine.

Basaglar may also interact with propoxyphene.

Side effects of Semglee include:

• low blood sugar (hypoglycemia),
• allergic reactions,
• injection site reactions,
• changes in body fat distribution (lipodystrophy),
• itching,
• rash,
• fluid retention (edema),
• and weight gain

Common side effects of Basaglar include:

• low blood sugar (hypoglycemia),
• allergic reactions,
• injection site reactions,
• body fat redistribution,
• itching,
• rash,
• swelling,
• weight gain,
• upper respiratory tract infection,
• runny or stuffy nose,
• back pain,
• cough,
• urinary tract infection,
• diarrhea,
• depression, or
• headache.

Semglee (insulin glargine injection) is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Basaglar (insulin glargine injection) is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Semglee may interact with other medicines such as:

• antidiabetic agents,
• ACE inhibitors,
• angiotensin II receptor blocking agents,
• disopyramide,
• fibrates,
• fluoxetine,
• monoamine oxidase inhibitors (MAOIs),
• pentoxifylline,
• pramlintide,
• salicylates,
• somatostatin analog (e.g., octreotide),
• sulfonamide antibiotics,
• atypical antipsychotics,
• corticosteroids,
• danazol,
• diuretics,
• estrogens,
• glucagon,
• isoniazid,
• niacin,
• oral contraceptives,
• phenothiazines,
• progestogens (e.g., in oral contraceptives),
• protease inhibitors,
• somatropin,
• sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),
• thyroid hormones
• ,
• alcohol,
• beta-blockers,
• clonidine,
• lithium salts,
• guanethidine, and
• reserpine

Tell your doctor all medications and supplements you use.

Basaglar may interact with antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs, sulfonamide antibiotics, atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetic agents, thyroid hormones, alcohol, beta-blockers, clonidine, lithium salts, guanethidine, and reserpine. Tell your doctor all medications and supplements you use.

The dose of Semglee is individualized based on the patient’s metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use.

The dose of Basaglar is individualized based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use.